AAME Logo White 225px

Keep FDA Safety Requirements and Nix Telemedicine Abortions

April 30, 2020

by Jonathan Imbody

Seeing the pandemic as an opportunity to pump up profits from abortions, the abortion industry and its advocates in state governments are lobbying to loosen abortion-related FDA safety requirements.

Twenty-one state attorneys general have written to U.S. Department of Health and Human Services Secretary Alex Azar and FDA Commissioner Stephen Hahn, “to request that you increase access to reproductive healthcare, including safe and legal abortion, during this pandemic. Specifically, as the U.S. Food & Drug Administration (FDA) considers policy changes in response to the Coronavirus Disease 2019 (COVID-19) public health emergency, we urge you to waive its Risk Evaluation and Mitigation Strategy (REMS), or use FDA enforcement discretion, to allow certified prescribers to use telehealth for Mifepristone, the medication abortion prescription drug.”

Thankfully, pro-life Members of Congress also have written to Azar and Hahn, urging the officials to protect the health of women.

Rep. Bob Latta (R-OH) led 38 Senators and 121 House Members in a bicameral letter that noted,

“Despite claims that medication abortion is safe and easy, research proves that as many as five to seven percent of women who take abortion drugs will require follow-up surgery, and three percent could end up in the emergency room. Self-managed abortions from home are especially dangerous; in fact, half of abortion providers do not consider them safe, according to a 2019 survey published in the journal Contraception. Further, medication abortion becomes even more dangerous in situations where women cannot access emergency medical care. This is especially concerning during the COVID-19 pandemic as emergency rooms are currently being overwhelmed.”

AAME President Jeffrey Barrows, DO, MA, (Ethics) notes:

“The FDA gave Mifepristone a REMS designation because it is a drug with significant complications if not prescribed correctly. One essential criterion for prescribing Mifepristone is to establish that the pregnancy is less than 71 days in duration. Telemedicine is incapable of correctly ascertaining the gestational length of a pregnancy. Menstrual history is an inaccurate indicator of gestational age, even among reliable patients. If Mifepristone is given inadvertently to a woman beyond 70 days gestation, the potential danger of hemorrhage and its resulting complications rise significantly, thus placing the patient at significant risk of harm.”

Abortion is not healthcare, much less essential healthcare during a pandemic.

Besides protecting women’s health, we also want to offer alternatives such as pregnancy resource centers and adoption. By loving both mother and baby, and by engaging in public policy with credibility and courage, we can begin to rebuild a culture of life in our nation.

 

Other Posts:

Photo: Pexels

U.S. Sends Shot Across Bow of UN, WHO with Multilateral, Pro-Life Health Declaration

November 5, 2020

The Geneva statement reflects the Protecting Life in Global Health Assistance policy of the United States. According to HHS, the policy “negotiates health policy at multilateral settings where policies are debated and set, like the World Health Organization (WHO) and the United Nations (UN).”

Photo: Pexels

Disassembling the Abortion vs. Childbirth Safety Myth

February 6, 2020

The abortion industry launched a lawsuit after the state of Louisiana passed Act 620, which required “that every physician who performs or induces an abortion shall ‘have active admitting privileges at a hospital that is located not further than thirty miles from the location at which the abortion is performed or induced.

Photo: Pexels

Administration Moves to Bind Human Tissue Research to Ethical Considerations

July 3, 2019

This courageous and right decision gets the government and our tax dollars out of the sordid business of using tissue from developing babies who have died as a result of elective abortions.